메뉴 건너뛰기




Volumn 12, Issue 10, 2011, Pages 1661-1663

Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma

Author keywords

bortezomib; induction therapy; multiple myeloma; novel agents

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

EID: 79958749318     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.575780     Document Type: Article
Times cited : (2)

References (12)
  • 1
    • 78049488759 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 Phase III trial
    • Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III trial. J Clin Oncol 2010;28(30):4621-9
    • (2010) J Clin Oncol , vol.28 , Issue.30 , pp. 4621-4629
    • Harousseau, J.L.1    Attal, M.2    Avet-Loiseau, H.3
  • 2
    • 70350433797 scopus 로고    scopus 로고
    • The role of complete response in multiple myeloma
    • Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114(15):3139-46
    • (2009) Blood , vol.114 , Issue.15 , pp. 3139-46
    • Harousseau, J.L.1    Attal, M.2    Avet-Loiseau, H.3
  • 3
    • 36349031205 scopus 로고    scopus 로고
    • Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
    • DOI 10.3324/haematol.11534
    • van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92(10):1399-406 (Pubitemid 350144158)
    • (2007) Haematologica , vol.92 , Issue.10 , pp. 1399-1406
    • Van De Velde, H.J.K.1    Liu, X.2    Chen, G.3    Cakana, A.4    Deraedt, W.5    Bayssas, M.6
  • 5
    • 78650303638 scopus 로고    scopus 로고
    • Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104
    • McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts. 2010;28(15 Suppl):8017
    • (2010) ASCO Meeting Abstracts , vol.28 , Issue.15 SUPPL. , pp. 8017
    • McCarthy, P.L.1    Owzar, K.2    Anderson, K.C.3
  • 6
    • 79952836604 scopus 로고    scopus 로고
    • Maintenance treatment with lenalidomide after transplantation for MYELOMA: Final analysis of the IFM 2005-02
    • ASH Annual Meeting Abstracts
    • Attal M, Lauwers Vc, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: Final analysis of the IFM 2005-02. ASH Annual Meeting Abstracts. Blood 2010;116(21):310
    • (2010) Blood , vol.116 , Issue.21 , pp. 310
    • Attal, M.1    Lauwers, V.C.2    Marit, G.3
  • 7
    • 77955980661 scopus 로고    scopus 로고
    • Bortezomib Plus Dexamethasone (VD) Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)
    • Harousseau J-L, Avet-Loiseau H, Facon T, et al. Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2009;114(22):354
    • (2009) ASH Annual Meeting Abstracts , vol.114 , Issue.22 , pp. 354
    • Harousseau, J.-L.1    Avet-Loiseau, H.2    Facon, T.3
  • 8
    • 79952790841 scopus 로고    scopus 로고
    • HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide in Patients with Newly Diagnosed Multiple Myeloma (MM)
    • Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2010;116(21):40
    • (2010) ASH Annual Meeting Abstracts , vol.116 , Issue.21 , pp. 40
    • Sonneveld, P.1    Schmidt-Wolf, I.2    Van Der Holt, B.3
  • 9
    • 77955452192 scopus 로고    scopus 로고
    • Velcade Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial)
    • Einsele H, Liebisch P, Langer C, et al. Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). ASH Annual Meeting Abstracts 2009;114(22):131
    • (2009) ASH Annual Meeting Abstracts , vol.114 , Issue.22 , pp. 131
    • Einsele, H.1    Liebisch, P.2    Langer, C.3
  • 10
    • 67650882695 scopus 로고    scopus 로고
    • Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a Phase II clinical trial
    • Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a Phase II clinical trial. Leukemia 2009;23(7):1337-41
    • (2009) Leukemia , vol.23 , Issue.7 , pp. 1337-41
    • Reeder, C.B.1    Reece, D.E.2    Kukreti, V.3
  • 11
    • 77954618168 scopus 로고    scopus 로고
    • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    • Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86
    • (2010) Blood , vol.116 , Issue.5 , pp. 679-86
    • Richardson, P.G.1    Weller, E.2    Lonial, S.3
  • 12
    • 77954660886 scopus 로고    scopus 로고
    • Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter evolution study
    • Kumar SK, Flinn I, Noga SJ, et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter evolution study. Leukemia 2010;24(7):1350-6
    • (2010) Leukemia , vol.24 , Issue.7 , pp. 1350-6
    • Kumar, S.K.1    Flinn, I.2    Noga, S.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.